Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGNDZ) Return on Sales (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Return on Sales for 15 consecutive years, with 0.75% as the latest value for Q4 2025.

  • Quarterly Return on Sales rose 148.0% to 0.75% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.46% through Dec 2025, up 65.0% year-over-year, with the annual reading at 0.46% for FY2025, 49.0% up from the prior year.
  • Return on Sales hit 0.75% in Q4 2025 for Ligand Pharmaceuticals, down from 1.02% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 1.02% in Q3 2025 to a low of 0.94% in Q1 2025.
  • Historically, Return on Sales has averaged 0.05% across 5 years, with a median of 0.07% in 2022.
  • Biggest five-year swings in Return on Sales: plummeted -71bps in 2024 and later skyrocketed 148bps in 2025.
  • Year by year, Return on Sales stood at 0.04% in 2021, then tumbled by -49bps to 0.06% in 2022, then surged by 78bps to 0.01% in 2023, then plummeted by -5627bps to 0.73% in 2024, then soared by 203bps to 0.75% in 2025.
  • Business Quant data shows Return on Sales for LGNDZ at 0.75% in Q4 2025, 1.02% in Q3 2025, and 0.1% in Q2 2025.